AR DHTR NR3C4

AR ;
DHTR ;
NR3C4 ;
Androgen receptor ;
Dihydrotestosterone receptor ;
Nuclear receptor subfamily 3 group C member 4

disease:Defects in AR are the cause of androgen insensitivity syndrome (AIS) [MIM:300068]; previously known as testicular feminization syndrome (TFM) . AIS is an X-linked recessive form of pseudohermaphroditism due end-organ resistance to androgen. Affected males have female external genitalia , female breast development , blind vagina , absent uterus and female adnexa , and abdominal or inguinal testes , despite a normal 46 ,XY karyotype. ,disease:Defects in AR are the cause of androgen insensitivity syndrome partial (PAIS) [MIM:312300]; also known as Reifenstein syndrome. PAIS is characterized by hypospadias , hypogonadism , gynecomastia , genital ambiguity , normal XY karyotype , and a pedigree pattern consistent with X-linked recessive inheritance. Some patients present azoospermia or severe oligospermia without other clinical manifestations. ,disease:Defects in AR are the cause of spinal and bulbar muscular atrophy X-linked type 1 (SMAX1) [MIM:313200]; also known as Kennedy disease. SMAX1 is an X-linked recessive form of spinal muscular atrophy. Spinal muscular atrophy refers to a group of neuromuscular disorders characterized by degeneration of the anterior horn cells of the spinal cord , leading to symmetrical muscle weakness and atrophy. SMAX1 occurs only in men. Age at onset is usually in the third to fifth decade of life , but earlier involvement has been reported. It is characterized by slowly progressive limb and bulbar muscle weakness with fasciculations , muscle atrophy , and gynecomastia. The disorder is clinically similar to classic forms of autosomal spinal muscular atrophy. SMAX1 is caused by trinucleotide CAG repeat expansion. In SMAX1 patients the number of Gln ranges from 38 to 62. Longer expansions result in earlier onset and more severe clinical manifestations of the disease. ,disease:Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor. ,domain:Composed of three domains: a modulating N-terminal domain , a DNA-binding domain and a C-terminal steroid-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain , and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain. ,function:Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated , but not phosphorylated , by HIPK3. ,miscellaneous:In the absence of ligand , steroid hormone receptors are thought to be weakly associated with nuclear components; hormone binding greatly increases receptor affinity. The hormone-receptor complex appears to recognize discrete DNA sequences upstream of transcriptional start sites. ,miscellaneous:The level of tyrosine phosphorylation may serve as a diagnostic tool to predict patient outcome in response to hormone-ablation therapy. Inhibition of tyrosine phosphorylation may be an effective intervention target for hormone-refractory prostate cancer. ,miscellaneous:Transcriptional activity is enhanced by binding to RANBP9. ,online information:Androgen receptor entry ,polymorphism:The poly-Gln region of AR is highly polymorphic and the number of Gln varies in the population (from 17 to 26) . A smaller size of the poly-Gln region may be associated with the development of prostate cancer. ,polymorphism:The poly-Gly region of AR is polymorphic and ranges from 24 to 31 Gly. A poly-Gly region shorter or equal to 23 may be associated with the development of androgenetic alopecia. ,PTM:Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK) . Tyr-534 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. ,PTM:Sumoylated on Lys-386 (major) and Lys-520. ,similarity:Belongs to the nuclear hormone receptor family. ,similarity:Belongs to the nuclear hormone receptor family. NR3 subfamily. ,similarity:Contains 1 nuclear receptor DNA-binding domain. ,subunit:Binds DNA as a homodimer. Part of a ternary complex containing AR , EFCAB6/DJBP and PARK7. Interacts with HIPK3 and NR0B2 in the presence of androgen. The ligand binding domain interacts with MYST2/HBO1 in the presence of dihydrotestosterone. Interacts with EFCAB6/DJBP , PELP1 , PQBP1 , RANBP9 , RBAK , SPDEF , SRA1 , TGFB1I1 , ZNF318 and RREB1. Interacts with ZMIZ1/ZIMP10 and ZMIZ2/ZMIP7 which both enhance its transactivation activity. Interacts with SLC30A9 and RAD54L2/ARIP4 (By similarity) . Interacts via the ligand-binding domain with LXXLL and FXXLF motifs from NCOA1 , NCOA2 , NCOA3 , NCOA4 and MAGEA11. The AR N-terminal poly-Gln region binds Ran resulting in enhancement of AR-mediated transactivation. Ran-binding decreases as the poly-Gln length increases. Interacts with HIP1 (via coiled coil domain) . ,tissue specificity:Isoform 2 is mainly expressed in heart and skeletal muscle. ,

urogenital system development , in utero embryonic development , reproductive developmental process , transcription ,transcription , DNA-dependent , regulation of transcription , DNA-dependent , regulation of transcription from RNA polymerase II promoter , intracellular signaling cascade , cell-cell signaling , sex determination , sex differentiation , cell death , cell proliferation , regulation of cell size , gonad development , male gonad development , response to endogenous stimulus , response to hormone stimulus , embryonic development ending in birth or egg hatching , positive regulation of biosynthetic process , response to organic substance , positive regulation of macromolecule biosynthetic process , positive regulation of macromolecule metabolic process , positive regulation of gene expression , cell growth ,death , somatic sex determination , male somatic sex determination , male sex determination , steroid hormone receptor signaling pathway , androgen receptor signaling pathway , intracellular receptor-mediated signaling pathway , prostate gland development , positive regulation of cellular biosynthetic process , regulation of cellular component size , RNA biosynthetic process , response to insulin stimulus , growth , chordate embryonic development , response to peptide hormone stimulus , development of primary sexual characteristics , regulation of transcription , positive regulation of transcription , DNA-dependent , positive regulation of nucleobase , nucleoside , nucleotide and nucleic acid metabolic process , positive regulation of transcription , positive regulation of transcription from RNA polymerase II promoter ,development of primary male sexual characteristics , male sex differentiation , reproductive structure development ,gland development , positive regulation of nitrogen compound metabolic process , regulation of RNA metabolic process ,positive regulation of RNA metabolic process ,

Nucleus . Cytoplasm . Detected at the promoter of target genes (PubMed:25091737) . Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1. .